NCT02007226 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bauman WA, Spungen AM, Raza M, Rothstein J, Zhang RL, Zhong YG, Tsuruta M, Shahidi R, Pierson RN Jr, Wang J, et al
Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt Sinai J Med. 1992 Mar;59(2):163-8.
Bauman WA, Spungen AM
Carbohydrate and lipid metabolism in chronic spinal cord injury. J Spinal Cord Med. 2001 Winter;24(4):266-77. Review.
Bauman WA, Spungen AM
Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism. 1994 Jun;43(6):749-56.
Bauman WA, Spungen AM
Metabolic changes in persons after spinal cord injury. Phys Med Rehabil Clin N Am. 2000 Feb;11(1):109-40. Review.
Emmons RR, Garber CE, Cirnigliaro CM, Moyer JM, Kirshblum SC, Galea MD, Spungen AM, Bauman WA
The influence of visceral fat on the postprandial lipemic response in men with paraplegia. J Am Coll Nutr. 2010 Oct;29(5):476-81.

Coronary Artery Calcification (CAC) Score and Risk Factors for Coronary Artery Disease in Persons With Spinal Cord Injury(SCI)

Clinical trial NCT02007226 - References